Chung-Kuang Lu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4161807/publications.pdf

Version: 2024-02-01

1478505 1588992 8 108 6 8 citations h-index g-index papers 9 9 9 172 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Aberrant JAK/STAT Signaling Suppresses TFF1 and TFF2 through Epigenetic Silencing of GATA6 in Gastric Cancer. International Journal of Molecular Sciences, 2016, 17, 1467.	4.1	26
2	Inhibition of CCAR1, a Coactivator of \hat{l}^2 -Catenin, Suppresses the Proliferation and Migration of Gastric Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 460.	4.1	25
3	<i>Fusobacterium nucleatum </i> colonization is associated with decreased survival of <i>helicobacter pylori</i> positive gastric cancer patients. World Journal of Gastroenterology, 2021, 27, 7311-7323.	3.3	19
4	Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterology, 2021, 21, 259.	2.0	11
5	2,4-Diamino-Quinazoline, a Wnt Signaling Inhibitor, Suppresses Gastric Cancer Progression and Metastasis. International Journal of Molecular Sciences, 2020, 21, 5901.	4.1	8
6	Realâ€world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan. Journal of Viral Hepatitis, 2020, 27, 866-872.	2.0	8
7	Limited effects of antibiotic prophylaxis in patients with Child–Pugh class A/B cirrhosis and upper gastrointestinal bleeding. PLoS ONE, 2020, 15, e0229101.	2.5	8
8	Pangenotypic directâ€acting antiviral agents for mixed genotype hepatitis C infection: A realâ€world effectiveness analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2911-2916.	2.8	3